Introduction
============

Colorectal cancer (CRC) is one of the most common malignant tumors in China, with 376,300 new cases and 191,000 disease-related deaths in 2015 ([@ref-5]). The outcome of CRC patients has significantly improved over the past decades, but the identification of clinically actionable oncogenic drivers and related predicted biomarkers are largely elusive.

Previous studies have evaluated variety of genetic changes that appear to influence the prognosis of CRC patients, including microsatellite instability (MSI), *RAS* mutation, *BRAF* mutation, the human epidermal growth factor receptor 2 gene (*HER2*) ([@ref-6]; [@ref-19], [@ref-21]; [@ref-25]; [@ref-28]). *HER2* gene, which is located on chromosome 17q21, is a tyrosine kinase receptor and encodes for a 185-kDa transmembrane protein ([@ref-28]). *HER2* gene has been evidenced as a proto-oncogene and identified in many cancer types, including breast, gastric and CRC ([@ref-4]; [@ref-30]; [@ref-38]). *HER2* gene amplification plays a pivotal role in tumor growth and metastasis. In advanced stage CRC, patients with *HER2* amplification tumors were resistant to cetuximab-based treatment ([@ref-28]). Therefore, the accurate assessment of *HER2* gene amplification status in CRC appears to be particularly important for patients who might undertake this specific targeted therapy.

*BRAF* gene is another important molecular marker for malignancies. *BRAF* gene mutation can activate the RAF/MAPK pathway independently of epidermal growth factor receptor (*EGFR*) activation, leading to poor response to *EGFR* monoclonal antibody (Cetuximab) ([@ref-6]). In additional, detection of *BRAF* mutation is useful to distinguish sporadic MSI CRCs from Lynch syndrome ([@ref-22]), and the presence of *BRAF* mutation is associated with worse prognosis in metastatic CRC (mCRC) patients ([@ref-3]; [@ref-29]). But in early stage CRC patients, the prognostic role of *BRAF* mutations is controversial ([@ref-10]; [@ref-33]). A study conducted by European scholars showed *BRAF* mutation was an independent prognostic factor in stage II and III CRC ([@ref-9]), and a meta-analysis based on randomized clinical trials showed *BRAF* mutation patients presented poor response to adjuvant chemotherapy ([@ref-44]); however, Chinese scholars demonstrated *BRAF* mutation did not have prognostic value in stage II and III CRC patients ([@ref-31]).

Several studies had reported the frequency of *BRAF* mutation in CRC patients, but the number of samples was limited in most of studies. The mutation rate was 5--20% in western countries ([@ref-24]; [@ref-33]). But in Chinese, only 5% CRC patients harbored *BRAF* mutation ([@ref-32]; [@ref-40]; [@ref-41]). Moreover, the predictive value about this gene in Chinese patients with early stage CRC was also unclear. In addition, information about *HER2* amplification in Chinese CRC patients was limited ([@ref-18]). Some studies ([@ref-16]; [@ref-34]) demonstrated patients with *HER2* amplification tumor had a worse survival, but other studies ([@ref-26]; [@ref-27]) argued no meaningful relationships between this marker and survival. Therefore, in the present study, we analyzed the *HER2* amplification and *BRAF* V600E mutation status of CRC patients to evaluate possible associations between *HER2* and *BRAF* V600E mutation and the clinicopathological characteristics in primary stage I--III CRC, and we also attempted to explore the prognostic role of *HER2* and *BRAF* V600E mutation.

Materials and Methods
=====================

Four hundred and eighty formalin-fixed, paraffin-embedded tumor specimens from stage I--III CRC patients who underwent primary surgical resection from 2014 to 2016 in the Affiliated Hospital of Qingdao University were selected for this study. Patients who had undergone preoperative radiotherapy, chemotherapy and/or EGFR-targeted therapy were not included in this study. The clinic and pathologic variables were collected as previous description ([@ref-42]). The patients were followed up until December 2018, and the data concerning cancer recurrence and patient survival were collected. The study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University (QDFY-20130049).

*HER2* amplification analysis by immunohistochemistry and fluorescence in situ hybridization
--------------------------------------------------------------------------------------------

Immunohistochemistry (IHC) staining was performed on an Automated Staining System (BenchMark XT, Ventana Medical Systems, Inc., Oro Valley, AZ, USA). In brief, after deparaffinization and rehydration, paraffin-embedded tissue sections were blocked with CC1 citrate buffer (pH 6.0; Ventana) for 30 min, and incubated with *HER*2 specific monoclonal rabbit antibody (clone 4B5, Ventana Medical Systems Inc., Oro Valley, AZ, USA, working solution) at 37 °C for 32 min. Then, the tissue sections were incubated with 3,3′-diaminobenzidine (DAB) for 4 min. Counterstaining was performed with hematoxylin and bluing reagent for 4 min. The results were analyzed by two pathologists according to the scoring criteria described by [@ref-1]. The IHC staining was scored: 0 (no staining or membrane staining in less than 10% of tumor cells), 1+ (faint/barely visible membrane staining in at least 10% of cells or staining in parts of their membrane), 2+ (weak to moderate complete, basolateral, or lateral membrane staining in at least 10% of tumor cells), 3+ (strong complete or basolateral membrane staining in at least 10% of tumor cells) ([Figure 1](#fig-1){ref-type="fig"}).

![Immunohistochemical staining for human epidermal growth factor receptor 2 (*HER2*) in colorectal cancer.\
(A--D) The intensity of staining was scored as negative (0, A), weak (1+, B), moderate (2+, C) and strong (3+, D). Allimages are at 100× magnification.](peerj-08-8602-g001){#fig-1}

Samples with 2+ to 3+ IHC staining were retested by fluorescence in situ hybridization (FISH), using the PathVysion *HER2* DNA probe kit and procedure (Vysis/Abbott, Abbott Park, IL, USA). After deparaffinizated and rehydration, paraffin-embedded tissue sections (5 μm thick) were pretreatment at 82 °C for 10 min, then blocked with proteinase at 37 °C for 30 min. After 70% alcohol, tissue sections were denaturation at 75 °C for 10 min and hybridization with *HER2* DNA probe (10 µl) at 37 °C for 24 h, then counterstaining with 4′,6-diamidino-2-phenylindole (DAPI). The scoring for in situ hybridization was performed by counting *HER2* (labeled with Spectrum-Orange) and CEP17 (chromosome 17 enumeration probe labeled with Spectrum-Green) signals from no less than 20 non-overlapping tumor nuclei. Non-tumor tissue (normal colon mucosa) was used as an internal negative control. Samples with a *HER2*/CEP17 ratio ≥2.0, or the presence of tight gene clusters as recently reported ([@ref-37]) were considered as amplified, otherwise samples were defined as negative for *HER2*. FISH staining was evaluated by two different pathologists to ensure consistency ([Figure 2](#fig-2){ref-type="fig"}).

![FISH staining for human epidermal growth factor receptor 2 (*HER2*) in colorectal cancer.\
(A and B) The intensity of staining was scored as positive: *HER2*/CEP17 ratio was 2.3 in 20 tumor nuclei (A) and negative: *HER2*/CEP17 ratio was 1.58 in 20 tumor nuclei (B). All images are at 1,000× magnification.](peerj-08-8602-g002){#fig-2}

Analysis of *BRAF* V600E mutation by immunohistochemistry and Sanger sequencing
-------------------------------------------------------------------------------

Immunohistochemistry staining and Sanger sequencing for *BRAF* mutation were performed as previously described by [@ref-43]. In brief, after deparaffinization and rehydration, paraffin-embedded tissue sections (3 μm thick) were blocked with 3% hydrogen peroxide for 4 min at room temperature, treated with heat-induced antigen retrieval CC1 solution for 32 min, and incubated with *BRAF* V600E specific monoclonal mouse antibody (clone VE1, item code 790--4855, Ventana Medical Systems Inc., Oro Valley, AZ, USA, working solution) at 37 °C for 32 min. Then, the tissue sections were incubated with OptiView HRP Linker for 12 min, OptiView HRP multimer for 12 min, and developed with DAB for 4 min. Counterstaining was performed with hematoxylin and bluing reagent for 4 min. The results were analyzed by two pathologists according to the scoring criteria described by [@ref-43]. *BRAF* V600E expression within the cytoplasm was subjectively graded as: 0, no cytoplasmic staining visualized at any magnification; 1+, weak, requiring a 10× or greater objective to recognize flavescent staining on the section; 2+, moderate, easy to recognize yellow staining with a 10× objective; and 3+, strong brown staining with a 10× microscopic objective ([Figure 3](#fig-3){ref-type="fig"}).

![Immunohistochemical staining for *BRAF* V600E in colorectal cancer.\
(A--D) The intensity of staining was scored as negative (0, A), weak (1+, B), moderate (2+, C) and strong (3+, D). All images are at 100× magnification.](peerj-08-8602-g003){#fig-3}

All CRC cases with cytoplasmic staining were retested by Sanger sequencing analysis to exclude false positive. DNA was extracted using the Blood and Tissue DNA retraction Kit (Tiangen Inc., Beijing, China). Primers were designed to amplify the V600E point mutation. The sequence of the forward primer was 5′-TCATCCTAACACATTTCAAGCC-3′ and the reverse primer was 5′-GTAAAACGACGGCCAGTTTTGTGAATACTGGGAACTATGAAA-3′. PCR amplification conditions: 95 °C for 3 min, followed by 45 cycles of 94 °C for 15 s, 60 °C for 45 s, with a final cooling time for 1 min at 25 °C. The PCR products were purified with QIAquick Gel Extraction Kit (Qiagen). The cycling conditions were as follows: 96 °C for 1 min, followed by 30 cycles of 96 °C for 10 s, 50 °C for 5 s, with a final extension at 60 °C for 2 min. Purified products were then run on an ABI 3500 DX Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and analyzed using software supplied by the manufacturer ([@ref-43]). Both forward and reverse strands were sequenced. The sequences were compared with the database sequence in GenBank sequence database (HGNC: 1097) ([Figure 4](#fig-4){ref-type="fig"}).

![Sanger sequencing for *BRAF* V600E in colorectal cancer.\
(A), *BRAF* V600E wildtype by Sanger sequencing, (B) *BRAF* V600E *mutation* by Sanger sequencing.](peerj-08-8602-g004){#fig-4}

Statistical analysis
--------------------

Results were analyzed with SPSS 19.0 (SPSS, Inc., Chicago, IL, USA). For comparison of the frequencies among groups, Chi-square test and Fisher exact test were used. Survival curves for disease-free survival (DFS) and overall survival (OS) were estimated using Kaplan-Meier analysis with the log-rank test. Multivariable analysis was performed using Cox regression. Probability (*P*) value \<0.05 was considered as statistical significance.

Results
=======

*HER2* status and associations with clinicopathological characteristics
-----------------------------------------------------------------------

HER2 IHC scores of 3+, 2+, 1+ and 0 were observed in 10 (2.1%), 54 (11.3%), 86 (17.9%) and 330 (68.7%) tumors, respectively. *HER2* gene amplification was seen in 27 samples (9 cases with *HER2* IHC scores of 3+, 18 cases with *HER2* IHC scores of 2+) ([Supplemental Files](#supplemental-information){ref-type="supplementary-material"}). The amplification rate of *HER2* in CRC was 5.63% (27/480). *HER2* status and clinicopathological characteristics, including age, gender, tumor location, tumor size, histological characteristics, TNM stage and family medication history are shown in [Table 1](#table-1){ref-type="table"}. *HER2* amplification was significantly correlated with greater bowel wall invasion (*P* = 0.041) and more advanced TNM stage (I vs II vs III; 0 vs 5.78% vs 7.41%, *P* = 0.013). Although *HER2* amplification tumors were present more often in patients with CRC family history, there is no significant statistical difference in this study (10.34% vs 6.59%, *P* \> 0.05).

10.7717/peerj.8602/table-1

###### Correlations between *HER2* and *BRAF* gene mutation and clinicopathological characteristics (*n* = 480).

![](peerj-08-8602-g006)

![](peerj-08-8602-g007)

  Characteristics             Number   *BRAF*   *P*    *HER2*                                 *P*           
  --------------------------- -------- -------- ------ -------------------------------------- ----- ------- ---------------------------------------
  Gender                                                                                                    
  Male                        288      10       3.47   0.51                                   18    6.25    0.55
  Female                      192      9        4.69                                          9     4.69    
  Age (year)                                                                                                
  ≤50                         63       3        4.76   0.72[\*](#table-1fn1){ref-type="fn"}   5     7.94    0.38[\*](#table-1fn1){ref-type="fn"}
  \>50                        417      16       3.84                                          22    5.28    
  Location                                                                                                  
  Right side colon            105      3        2.86   0.19[\*](#table-1fn1){ref-type="fn"}   5     4.76    0.99
  Left side colon             87       7        8.05                                          6     6.90    
  Rectum                      269      9        3.35                                          16    5.95    
  Mucin production                                                                                          
  With                        415      15       3.61   0.31[\*](#table-1fn1){ref-type="fn"}   23    5.54    0.77[\*](#table-1fn1){ref-type="fn"}
  Without                     65       4        6.15                                          4     6.15    
  Tumor differentiation                                                                                     
  Poor                        103      8        7.77   0.04[\*](#table-1fn1){ref-type="fn"}   5     4.85    0.71
  Moderate/well               377      11       2.92                                          22    5.84    
  Tumor stage                                                                                               
  I                           66       2        3.03   0.62                                   0     0.00    0.013[\*](#table-1fn1){ref-type="fn"}
  II                          225      11       4.89                                          13    5.78    
  III                         189      6        3.17                                          14    7.41    
  Bowel wall invasion (T)                                                                                   
  T1+T2                       90       2        2.22   0.55[\*](#table-1fn1){ref-type="fn"}   1     1.11    0.041[\*](#table-1fn1){ref-type="fn"}
  T3+T4                       390      17       4.36                                          26    667     
  Tumor diameter                                                                                            
  \<5 cm                      261      7        2.68   0.18                                   14    5.36    0.97
  ≥5 cm                       219      12       5.48                                          13    5.94    
  Lymph node metastasis (N)                                                                                 
  With                        189      6        4.47   0.48                                   13    6.88    0.17
  Without                     291      13       3.17                                          14    4.81    
  Lymphovascular invasion                                                                                   
  No                          332      14       4.22   0.66                                   17    5.12    0.47
  Yes                         148      5        3.38                                          10    6.76    
  Alcohol intake                                                                                            
  Ever                        99       2        2.02   0.39[\*](#table-1fn1){ref-type="fn"}   4     4.04    0.44
  Never                       381      17       4.46                                          23    6.03    
  Smoking                                                                                                   
  Ever                        129      3        2.33   0.27                                   8     6.20    0.74
  Never                       351      16       4.56                                          19    4.69    
  Cancer family history                                                                                     
  Yes                         92       3        3.26   0.99                                   7     7.61    0.61
  No                          119      4        3.36                                          8     6.72    
  Unknown                     269                                                                           
  Colorectal family history                                                                                 
  Yes                         29       0        0.00   0.59[\*](#table-1fn1){ref-type="fn"}   3     10.34   0.49[\*](#table-1fn1){ref-type="fn"}
  No                          182      7        3.85                                          12    6.59    
  Unknown                     269                                                                           
  MSI status                                                                                                
  MSI                         72       4        5.56   0.51[\*](#table-1fn1){ref-type="fn"}   4     5.56    0.98[\*](#table-1fn1){ref-type="fn"}
  MSS                         408      15       3.68                                          23    5.63    
  *RAS* status                                                                                              
  Mutation                    207      0        0      0.001                                  2     3.48    0.001
  Wildtype                    273      19       6.95                                          25    9.12    

**Note**:

Fisher exact test were used.

*BRAF* V600E status and associations with clinicopathological characteristics
-----------------------------------------------------------------------------

Immunohistochemistry testing showed 26 cases with positive staining and 454 cases with negative staining. The distribution of positive IHC staining was 3+ in 12 cases, 2+ in 8 cases, and 1+ in 6 cases in CRCs ([Supplemental Files](#supplemental-information){ref-type="supplementary-material"}). Sanger sequencing showed 19 samples (12 cases with 3+ and 7 cases with 2+) harbored *BRAF* V600E mutation, so the mutation rates of *BRAF* V600E were 3.96% (19/480). Patients suffering from tumors with poor differentiation had a higher incidence rate of *BRAF* V600E mutation compared with those having tumors with moderate/well differentiation (7.77% vs 2.92%, *P* = 0.04). No significant difference between *BRAF* V600E mutation and other clinicopathological characteristics was found in present study ([Table 1](#table-1){ref-type="table"}).

Prognostic value of *HER2* amplification and *BRAF* V600E mutation in stage I--III CRC
--------------------------------------------------------------------------------------

Univariable analysis by Kaplan-Meier survival analysis and log-rank test was performed to evaluate the significance of clinicopathological factors for DFS and OS. We found that factors with statistical significance for DFS were age (*P* = 0.04), tumor differentiation (*P* = 0.002), bowel wall invasion (*P* = 0.04), lymph node metastasis (*P* = 0.03), lymphovascular invasion (*P* = 0.001) and *HER2* amplification (*P* = 0.007). Factors that were statistically significant for OS were age (*P* = 0.04), tumor differentiation (*P* = 0.03), tumor stage (*P* = 0.001), bowel wall invasion (*P* = 0.01), lymph node metastasis (*P* = 0.001) and lymphovascular invasion (*P* = 0.001) ([Table 2](#table-2){ref-type="table"}).

10.7717/peerj.8602/table-2

###### Univariate analysis of prognostic factors influencing disease free survival (DFS) and overall survival (OS) in stage I--III colorectal cancer.

![](peerj-08-8602-g008)

  Characteristics                                 DFS                    *P*     OS                    *P*
  ----------------------------------------------- ---------------------- ------- --------------------- -------
  Gender                                                                                               
  Male vs female                                  1.13 \[0.71--1.83\]    0.6     1.18 \[0.7--2.0\]     0.54
  Age (year)                                                                                           
  ≤50 vs \>50                                     0.49 \[0.25--0.97\]    0.04    0.47 \[0.22--0.97\]   0.04
  Location                                                                                             
  Right side colon vs left side colon vs rectum   0.73                           0.85                  
  Mucin production                                                                                     
  With vs without                                 1.75 \[0.89--3.47\]    0.11    1.8 \[0.85--3.80\]    0.12
  Tumor differentiation                                                                                
  Poor vs moderate/well                           2.56 \[1.40--4.68\]    0.002   2.08 \[1.09--3.99\]   0.03
  Tumor stage                                                                                          
  I vs II vs III                                                         0.06                          0.001
  Bowel wall invasion (T)                                                                              
  T1+T2 vs T3+T4                                  0.54 \[0.30--0.97\]    0.04    0.44 \[0.23--0.85\]   0.01
  Tumor diameter                                                                                       
  ≤5 cm vs \>5 cm                                 1.17 \[0.73--1.88\]    0.5     1.11 \[0.66--1.86\]   0.7
  Lymph node metastasis (N)                                                                            
  Without vs with                                 0.59 \[0.36--0.95\]    0.03    0.39 \[0.23--0.66\]   0.001
  Lymphovascular invasion                                                                              
  No vs yes                                       0.41 \[0.24--0.69\]    0.001   0.42 \[0.23--0.75\]   0.001
  Alcohol intake                                                                                       
  Ever vs never                                   1.1 \[0.62--1.94\]     0.75    0.97 \[0.52--1.81\]   0.91
  Smoking                                                                                              
  Ever vs never                                   1.3 \[0.77--2.19\]     0.32    0.99 \[0.55--1.77\]   0.97
  Cancer family history                                                                                
  Yes vs no                                       1.86 \[0.92--3.76\]    0.09    1.91 \[0.86--4.28\]   0.11
  Colorectal family history                                                                            
  Yes vs no                                       1.12 \[0.41--3.06\]    0.83    0.75 \[0.23--2.44\]   0.64
  MSI status                                                                                           
  MSI vs MSS                                      1.14 \[0.58--2.25\]    0.69    0.98 \[0.46--2.06\]   0.95
  *RAS* status                                                                                         
  *RAS* mutation vs *RAS* wildtype                1.35 \[0.84--2.19\]    0.21    1.45 \[0.86--2.25\]   0.16
  *BRAF* status                                                                                        
  *BRAF* mutation vs *BRAF* wildtype              3.41 \[0.91--12.74\]   0.07    1.08 \[0.25--4.68\]   0.92
  *HER2* status                                                                                        
  *HER2* amplification vs *HER2* negative         3.97 \[1.35--11.72\]   0.007   2.98 \[0.92--9.67\]   0.08

Patients with *HER2* amplification tumors were found to have significantly worse DFS (*P* = 0.007) ([Figure 5A](#fig-5){ref-type="fig"}). To determine the prognostic value independent of age distribution, tumor differentiation, bowel wall invasion, lymph node metastasis, lymphovascular invasion and *HER2* amplification were entered into a Cox regression model. Multivariate Cox regression analysis showed *HER2* amplification was an independent risk factor for worse DFS, tumors with *HER2* amplification were associated with a 2.53-fold increase in risk of cancer recurrence (HR = 2.53, 95% CI \[1.21--5.30\], *P* = 0.014) ([Table 3](#table-3){ref-type="table"}).

![Survival curves for disease free survival (DFS) and overall survival (OS) in stage I--III colorectal cancer according to *HER2* or *BRAF* status.\
(A) DFS according to *HER2* status; (B) OS according to *HER2* status; (C) DFS according to *BRAF* status; (D) OS according to *BRAF* status.](peerj-08-8602-g005){#fig-5}
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###### Independent prognostic factors correlating with disease free survival (DFS) in stage I--III colorectal cancer by Cox's regression analysis.

![](peerj-08-8602-g009)

  Characteristics              HR (95% CI)           *P*
  ---------------------------- --------------------- -------
  *HER2* amplification         2.53 \[1.21--5.30\]   0.014
  Tumor poor differentiation   1.91 \[1.16--3.14\]   0.011
  Lymphovascular invasion      2.15 \[1.34--3.44\]   0.001

Discussion
==========

HER2 and *BRAF* mutation are important for clinical treatment and prognosis evaluation in cancer patients. As we know, *HER2* has been found to be a predictive marker to *HER2*-targeted therapy in breast and gastric cancer; therefore, routine test for *HER2* status is mandatory in these tumors ([@ref-4]; [@ref-14]). The frequency of *BRAF* mutation in CRCs ranges from 5% to 15%, and *BRAF* mutation has been demonstrated to be a worse prognostic factor in mCRC ([@ref-3]) and should be tested for mCRC patients before MoAb treatment ([@ref-6]). No evidence has convinced that *HER2* gene amplification is a prognostic factor for CRC. [@ref-16] and [@ref-34] demonstrated patients with *HER2* amplification tumor had a worse survival, but some recent studies ([@ref-26]; [@ref-27]) argued no meaningful relationships between this marker and survival. Several studies had reported the frequency of *BRAF* mutation in Chinese CRC patients, but the number of samples was limited in most of the studies ([@ref-17]; [@ref-23]). Thus, we designed this study in Chinese population to explore the relationship between *HER2* amplification and *BRAF* mutation and clinicopathological parameters, and to evaluate prognostic and predictive values of *HER2* amplification and *BRAF* mutation for CRC.

In our study, the *HER2* gene amplification rate is 5.63%, similar to some other studies ([@ref-11]; [@ref-13]; [@ref-16]; [@ref-27]). However, report from Korea ([@ref-8]) showed the protein expression rate was 47%. There are several possible reasons for this discrepancy such as ethnic diversity and test methods, but the most likely reason for the divergent findings might be the different scoring systems. [@ref-8] judged only cytoplasmic staining in \>20% of tumor cells to be positive, so there was relatively higher positive rate in CRC. Nowadays, there are two different scoring systems for *HER2* IHC in CRC, gastroesophageal adenocarcinoma criteria (GEA criteria) and *HER2* Amplification for Colorectal Cancer Enhanced Stratification diagnostic criteria (HERACLES criteria) ([@ref-37]). The different criteria of membrane positivity may also cause for the conflicting results, [@ref-20] argued *HER2* status evaluated by the HERACLES criteria showed survival predictive for stage II--III CRC, but the results were not represented based on the GEA diagnostic criteria. In present study, the GEA criteria was used, and 33.3% (18/54) samples with IHC staining 2+ were confirmed to harbor *HER2* gene amplification, but [@ref-39] judged only 20% of tumors with *HER2* IHC 2+ staining showing gene amplification based on this criteria. IHC is a semiquantitative method and may be influenced by subjective perception of pathologists frequently, so exactly *HER2* positive standardized by IHC in CRC is urgently needed.

In our current study, we found *HER2* gene amplification was related to bowel wall invasion and advanced tumor stage, but several other studies have failed to show such relationship. [@ref-18] reported an association between *HER2* expression and tumor size and distant metastases, and a recent meta-analysis showed *HER2* amplification was associated with lymph node metastasis and advanced tumors stage ([@ref-35]). The number of studies suggests that *HER2* may play some role in tumor progression and would be a valuable prognostic factor for CRC patients ([@ref-16]; [@ref-34]). But in other studies, *HER2* gene amplification was higher in patients with more advanced stage or distant metastases, and no significant difference in prognosis for CRC patients ([@ref-26]; [@ref-39]).

The prognostic value of *HER2* amplification in CRC patients has been widely investigated, but no rationale had been obtained. A study from Germany indicated that *HER2* amplification resulted in poorer prognosis in all stage CRC ([@ref-12]), and [@ref-16] found that *HER2* amplification was significantly associated with worse prognosis in patients with stage III CRC. Moreover, some studies showed patients with *HER2* wild-type tumors have positive OS compared with those tumors containing amplified *HER2* due to benefit from anti-EGFR monoclonal antibody, and the targeted management may be an influential factor in patients with advanced CRC ([@ref-26]; [@ref-28]). In this study, we demonstrated that *HER2* amplification was independently associated with worse survival in DFS, considering that none of our patients received anti-EGFR treatment before recurrence, the influence in survival due to targeted management could be excluded. Therefore, we confirmed *HER2* amplification tumors had a higher propensity to recurrence and metastasize, and *HER2* amplification was an independent prognostic factor for DFS in stage I--III CRC.

In the present study, the mutation rates of *BRAF* was 3.96%, the *BRAF* mutation rate is similar to that previously reported in Iranian (5.8%, 15/258) ([@ref-24]), but significantly lower than the value of 16% among 1185 CRC patients from Norway ([@ref-33]). On the other hand, the association between *BRAF* mutations and clinicopathological characteristics has not been well known in Chinese CRC patients due to the insufficient number of CRCs with *BRAF* mutation. Nonetheless, reports from other countries have demonstrated that tumors with *BRAF* mutation are associated with tumor location, tumor grade, and mucinous production ([@ref-24]; [@ref-45]), our data confirmed *BRAF* mutations was only association with tumor differentiation. Several factors may be related to these differences, such as sample size, the distribution of age, stage, as well as racial and/or environmental differences.

Most previous studies demonstrated *BRAF* mutation was related to poorer outcomes ([@ref-15]; [@ref-33]; [@ref-36]). However, this evidence is mainly based on studies in western country, little is known about the prognostic role of *BRAF* mutations in eastern Chinese populations. Contrary to some previous studies, no associations of *BRAF* mutation with DFS and OS were found in eastern Chinese CRC patients in our study. In additional, in patients with mCRC, *BRAF* mutation acted as worse prognostic markers, and patients with *BRAF* mutations were less likely to achieve response to treatment with panitumumab or cetuximab ([@ref-7]; [@ref-29]; [@ref-2]). We did not evaluate the effect of panitumumab or cetuximab treatment after tumors achieved distant metastases, so the predictive value of *BRAF* mutation for monoclonal antibody treatment in stage IV CRC patients was unexplored. This is the preliminary study to explore the prognostic value of *BRAF* mutation in this area and further studies based on larger sample size and longer follow-up time are needed to confirm this finding.

Conclusion
==========

In summary, we investigated *HER2* and *BRAF* gene status in a series of stage I--III CRC patients in eastern China. Our data show the prevalence of *HER2* and *BRAF* mutation was 5.63% and 3.96%, respectively. *HER2* amplification appears to be associated with a worse DFS. More comprehensive molecular classification and survival analysis are needed to validate our findings.
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